NeuroBo Pharmaceuticals Analyst Ratings
NeuroBo Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 12/07/2022 | 322.54% | Ladenburg Thalmann | → $6 | Initiates Coverage On | → Buy |
| 02/01/2021 | 1026.76% | HC Wainwright & Co. | $20 → $16 | Maintains | Buy |
| 06/15/2020 | 1308.45% | HC Wainwright & Co. | → $20 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 2022 年 7 月 12 日 | 322.54% | 拉登堡塔尔曼 | → 6 美元 | 启动覆盖范围开启 | → 购买 |
| 2021 年 1 月 2 日 | 1026.76% | HC Wainwright & Co. | 20 美元 → 16 美元 | 维护 | 买 |
| 06/15/2020 | 1308.45% | HC Wainwright & Co. | → 20 美元 | 启动覆盖范围开启 | → 购买 |
What is the target price for NeuroBo Pharmaceuticals (NRBO)?
NeuroBo Pharmicals（NRBO）的目标价格是多少？
The latest price target for NeuroBo Pharmaceuticals (NASDAQ: NRBO) was reported by Ladenburg Thalmann on December 7, 2022. The analyst firm set a price target for $6.00 expecting NRBO to rise to within 12 months (a possible 322.54% upside). 1 analyst firms have reported ratings in the last year.
拉登堡·塔尔曼于2022年12月7日公布了NeuroBo Pharmicals（纳斯达克股票代码：NRBO）的最新目标股价。该分析公司将目标股价定为6.00美元，预计NRBO将在12个月内升至12个月内（可能上涨322.54％）。1家分析公司去年公布了评级。
What is the most recent analyst rating for NeuroBo Pharmaceuticals (NRBO)?
NeuroBo Pharmicals（NRBO）的最新分析师评级是多少？
The latest analyst rating for NeuroBo Pharmaceuticals (NASDAQ: NRBO) was provided by Ladenburg Thalmann, and NeuroBo Pharmaceuticals initiated their buy rating.
拉登堡·塔尔曼对NeuroBo Pharmicals（纳斯达克股票代码：NRBO）的最新分析师评级由拉登堡·塔尔曼提供，NeuroBo Pharmicals启动了
When is the next analyst rating going to be posted or updated for NeuroBo Pharmaceuticals (NRBO)?
NeuroBo Pharmicals（NRBO）的下一次分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NeuroBo Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NeuroBo Pharmaceuticals was filed on December 7, 2022 so you should expect the next rating to be made available sometime around December 7, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与NeuroBo Pharmicals的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。NeuroBo Pharmicals的最新评级是在2022年12月7日发布的，因此您应该预计下一个评级将在2023年12月7日左右公布。
Is the Analyst Rating NeuroBo Pharmaceuticals (NRBO) correct?
分析师对NeuroBo制药（NRBO）的评级是否正确？
While ratings are subjective and will change, the latest NeuroBo Pharmaceuticals (NRBO) rating was a initiated with a price target of $0.00 to $6.00. The current price NeuroBo Pharmaceuticals (NRBO) is trading at is $1.42, which is within the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的NeuroBo Pharmicals（NRBO）评级是启动的，目标股价为0.00美元至6.00美元。NeuroBo Pharmicals（NRBO）目前的交易价格为1.42美元，在分析师的预测区间内。